Comprehensive Management Conferring an Improved Outcome for a post –COVID-19 Patient With Congestive Heart Failure: A Case Report

Document Type : Case Report


1 Department of Internal Medicine, Faculty of Medicine, Universitas Islam Indonesia, Indonesia.

2 Department of Cardiology, Universitas Islam Indonesia Hospital and Panembahan Senopati Hospital, Indonesia.

3 Department of Anesthesiology and Intensive Care, Faculty of Medicine, Universitas Islam Indonesia, Indonesia.


Background: The COVID-19 pandemic has been unresolved for 3 years. Numerous individuals have survived COVID-19 but suffered from a variety of problems or symptoms for several months. This report presents our experience regarding a post–COVID-19 patient with exacerbated symptoms of congestive heart failure and congestive hepatopathy.
Result: Two months after being diagnosed with COVID-19, a 47-year-old man presented to Universitas Islam Indonesia Hospital with significant shortness of breath and abdominal enlargement. Cardiomegaly, increased jugular venous pressure, hepatomegaly, ascites, and bilateral edema of the legs were all indicators of congestive heart failure. Cardiomegaly was discovered on a chest X-ray. Electrocardiography revealed ischemic heart illness with an old myocardial infarction. Aspartate transaminase (911 U/L), alanine transaminase (820 U/L), and total bilirubin (4-6 mg/dL) were increased. Ultrasonography of the abdomen demonstrated congestive hepatopathy with ascites. Echocardiography showed hypokinetic cardiac wall movements and a 21% decrease in the ejection fraction. He had a comorbidity of uncontrolled diabetes mellitus. The symptoms subsided after therapy with furosemide, spironolactone, dobutamine, nebivolol, sacubitril, valsartan, L-ornithine-L-aspartate, insulin, and a broad spectrum of antibiotics. After 10 days of hospitalization with comprehensive management, the patient’s condition improved.
Conclusions: Our post–COVID-19 patient suffering from congestive heart failure with a poor ejection fraction and severe congestive hepatopathy had an improved outcome following our comprehensive management. (Iranian Heart Journal 2023; 24(3): 100-107)


  1. WHO, Coronavirus Disease. 2022.
  2. De Almeida-Pititto et al., “Severity and mortality of COVID 19 in patients with diabetes, hypertension and cardiovascular disease: A meta-analysis,” Diabetol. Metab. Syndr., vol. 12, no. 1, pp. 1–12, 2020, doi: 10.1186/s13098-020-00586-4.
  3. Landmesser, I. Lehmann, and R. Eils, “Hyperinflammation as underlying mechanism predisposing patients with cardiovascular diseases for severe COVID-19 ,” Eur. Heart J., vol. 42, no. 18, pp. 1720–1721, 2021, doi: 10.1093/eurheartj/ehab191.
  4. J. Clerkin et al., “COVID-19 and Cardiovascular Disease,” Circulation, vol. 141, no. 20, pp. 1648–1655, 2020, doi: 10.1161/CIRCULATIONAHA.120.046941.
  5. Italia et al., “COVID-19 and Heart Failure: From Epidemiology During the Pandemic to Myocardial Injury, Myocarditis, and Heart Failure Sequelae,” Front. Cardiovasc. Med., vol. 8, Aug. 2021, doi: 10.3389/fcvm.2021.713560.
  6. Linschoten et al., “Cardiac complications in patients hospitalised with COVID-19 ,” Eur. Hear. Journal. Acute Cardiovasc. Care, vol. 9, no. 8, pp. 817–823, 2020, doi: 10.1177/2048872620974605.
  7. Nishiga, D. W. Wang, Y. Han, D. B. Lewis, and J. C. Wu, “COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives,” Nat. Rev. Cardiol., vol. 17, no. 9, pp. 543–558, 2020, doi: 10.1038/s41569-020-0413-9.
  8. Petrovic, D. Radenkovic, G. Radenkovic, V. Djordjevic, and M. Banach, “Pathophysiology of Cardiovascular Complications in COVID-19 ,” Front. Physiol., vol. 11, no. October, pp. 1–11, 2020, doi: 10.3389/fphys.2020.575600.
  9. S. Ramadan, L. Bertolino, and R. Zampino, “Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID- 19 . The COVID-19  resource centre is hosted on Elsevier Connect , the company ’ s public news and information ,” no. January, 2020.
  10. Dan, M. Pant, and S. K. Upadhyay, “The Case Fatality Rate in COVID-19 Patients With Cardiovascular Disease: Global Health Challenge and Paradigm in the Current Pandemic,” Curr. Pharmacol. Reports, vol. 6, no. 6, pp. 315–324, 2020, doi: 10.1007/s40495-020-00239-0.
  11. Xie, E. Xu, B. Bowe, and Z. Al-Aly, “Long-term cardiovascular outcomes of COVID-19 ,” Nat. Med., vol. 28, no. 3, pp. 583–590, Mar. 2022, doi: 10.1038/s41591-022-01689-3.
  12. A. McDonagh et al., “2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure,” Eur. Heart J., vol. 42, no. 36, pp. 3599–3726, 2021, doi: 10.1093/eurheartj/ehab368.
  13. Management and D. L. Goldenberg, “COVID-19 Long Haulers : A Look at Cardiovascular Risk,” no. Cv, pp. 1–8.
  14. Williamson, “What COVID-19 is doing to the heart, even after recovery,” Am. Hear. Assoc. News, pp. 1–4, 2020, [Online]. Available: -is-doing-to-the-heart-even-after-recovery.
  15. Chilazi, E. Y. Duffy, A. Thakkar, and E. D. Michos, “COVID and Cardiovascular Disease: What We Know in 2021,” Curr. Atheroscler. Rep., vol. 23, no. 7, 2021, doi: 10.1007/s11883-021-00935-2.
  16. A. Bae, S. R. Kim, M. N. Kim, W. J. Shim, and S. M. Park, “Impact of cardiovascular disease and risk factors on fatal outcomes in patients with COVID-19 according to age: A systematic review and meta-analysis,” Heart, vol. 107, no. 5, pp. 373–380, 2021, doi: 10.1136/heartjnl-2020-317901.
  17. R. Anderson, “Post-COVID syndrome : How ’ s your heart ? By,” pp. 1–6, 2021.